News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

GPC Biotech AG (GPCG.DE) Announces Two Upcoming Corporate Events

5/15/2009 11:25:06 AM

MARTINSRIED/MUNICH, GERMANY and PRINCETON, NJ--(Marketwire - May 15, 2009) - GPC Biotech AG (FRANKFURT: GPC) today announced two corporate events as follows:

- The Company will hold a call to discuss first quarter financial results and provide a business update on May 28th. This call was previously planned for May 19th. The call will be held on May 28 at 15:00 CET/9:00 AM ET. The results will be published on May 28 in advance of the conference call.

Participants may listen via live webcast, accessible through the GPC Biotech Web site at, or via telephone. A replay will be available on the Web site following the live event. The call will be conducted in English. The dial-in numbers for the call are as follows:

Participants from Europe: +49 (0)69 667775756 or +44 (0)20 3003 2666

Participants from the U.S.: 1 646 843 4608

- The Company also announced that the Annual Shareholders' Meeting has been scheduled for June 23, 2009. At this meeting, shareholders will be asked to approve the merger agreement for the planned combination with Agennix, Incorporated in a new German company. The meeting will be held at 10:00 CET at the Alte Kongresshalle, Theresienhöhe 15 (Schwanthalerhöhe) in Munich. The agenda for the meeting and related documents are posted on the Company's website at in the Investor Relations section.

About GPC Biotech

GPC Biotech AG is a publicly traded biopharmaceutical company focused on developing anti-cancer drugs. The Company currently has two programs in clinical development: satraplatin, an oral platinum compound and RGB-286638, a multi-targeted protein kinase inhibitor. On February 18, 2009 the Company announced plans to combine its business with U.S.-based Agennix, Incorporated in a new German company. Agennix, a privately held biotechnology company, is developing oral talactoferrin, a product candidate that is currently in Phase 3 trials for non-small cell lung cancer. GPC Biotech AG is headquartered in Martinsried/Munich (Germany) and has a wholly owned U.S. subsidiary in Princeton, New Jersey. For additional information, please visit GPC Biotech's Web site at

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of GPC Biotech. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date on which they are made and GPC Biotech undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

For further information, please contact:
GPC Biotech AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565-2693

In the U.S.:
Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609-524-5884

Additional media contacts for Europe:
MC Services AG
Phone: +49 (0) 89 210 228 0

Raimund Gabriel

Hilda Juhasz

Additional investor contact for Europe:
Trout International LLC
Lauren Rigg
Vice President
Phone: +44 207 936 9325

Read at

Related News

comments powered by Disqus